A Phase 3 interventional study of Guselkumab and Placebo in Arthritis, Psoriatic, sponsored by Janssen Research & Development, LLC. Completed at 95 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-03.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing guselkumab in Arthritis, Psoriatic — 5 open to participants now, 8 under way, 3 of them phase 3. guselkumab · Arthritis, Psoriatic.
Among the 14 studies testing guselkumab in Arthritis, Psoriatic, this one is the 5th largest by enrollment, is one of 2 that started in 2017, is one of 7 in phase 3, and was the 3rd registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →5 of the 14 studies testing guselkumab in Arthritis, Psoriatic are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
NYU Langone Health · Sites in United States
Ages 18+
Johnson & Johnson Private Limited · Sites in India
Ages 18+
University of California, San Diego · Sites in United States
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 15 more countries
Ages 3+
By country, each count listing its studies:
guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 383 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 173 across the 14 interventional studies. Of the 6 that completed or were terminated, 4 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 14 have an industry lead sponsor. The 6 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
37 studies in Arthritis, Psoriatic by Johnson & Johnson: 5 open now, 13 under way, 5 of them phase 3. Of 23 finished, 13 (57%) have results posted.
Among the 37 studies in Arthritis, Psoriatic by Johnson & Johnson, this one is the 10th largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2017, is one of 15 in phase 3, and was the 19th registered.
Johnson & Johnson’s Arthritis, Psoriatic studies by the year they started, since 2002.
4 of the studies testing guselkumab in Arthritis, Psoriatic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04929210Janssen Research & Development, LLCA Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease | 2027-04-01 |
| NCT07141004Johnson & Johnson Private LimitedA Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA) | 2027-06-05 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
| NCT06586281University of California, San DiegoElucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies testing guselkumab in Arthritis, Psoriatic, from their registry updates:
Among Johnson & Johnson’s 37 in Arthritis, Psoriatic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active Psoriatic Arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
This is a study of guselkumab in participants with active Psoriatic Arthritis (PsA) who had inadequate response to standard therapies. It will evaluate the clinical efficacy of guselkumab in the reduction of signs and symptoms and the safety profile of guselkumab in the treatment of PsA. The study will consists of 4 phases: a screening phase of up to 6 weeks, a blinded treatment phase of approximately 1 year (that is, 52 weeks), including a placebo controlled period from Week 0 to Week 24 and double-blind active treatment period from Week 24 to Week 52, and a safety follow-up phase of 8 weeks after Week 52 (Week 52 to 60) and will be 12 weeks from the last administration of study agent (at Week 48) to the final safety follow-up visit. Efficacy, safety, pharmacokinetic, immunogenicity, and biomarker evaluations will be performed in the study at defined schedule.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive subcutaneous (SC) guselkumab 100 milligram (mg) once every 4 weeks (q4w) from Week 0 through Week 48.
Drug: Guselkumab
Participants will receive SC guselkumab 100 mg at Weeks 0 and 4, then once every 8 weeks (q8w) (Weeks 12, 20, 28, 36, and 44) and placebo injections at other visits (Weeks 8, 16, 24, 32, 40, 48) to maintain the blind.
Drug: Guselkumab · Drug: Placebo
Participants will receive SC placebo q4w from Week 0 to Week 20, and will crossover at Week 24 to receive guselkumab 100 mg q4w from Week 24 through Week 48.
Drug: Guselkumab · Drug: Placebo
Participants will receive 100mg of guselkumab as a sterile liquid for SC injection.
Also known as: CNTO 1959
Participants will receive matching placebo as SC injection.
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24
ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP. Treatment Failure (TF) criteria- discontinued study drug, initiated/increased dose of non-biologic disease-modifying antirheumatic drugs (DMARDs) or oral corticosteroids, initiated prohibited psoriatic arthritis treatment.
Time frame: Week 24
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
Time frame: Baseline and Week 24
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 24
ACR 50 response was defined as greater than or equal to (\>=)50 percent (%) improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and C-Reactive Protein (CRP).
Time frame: Week 24
Percentage of Participants With Psoriasis Response of IGA (Score: 0[Cleared] or 1[Minimal] and >=2 Grade Reduction From Baseline) at Week 24 Among Participants With >=3% Body Surface Area (BSA) Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline
A psoriasis Investigator's Global Assessment (IGA) response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Week 24
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16
ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform task in that area), and C-reactive protein (CRP).
Time frame: Week 16
Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24
The Disease Activity Index Score (DAS28) based on C-Reactive Protein (CRP) is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.
Time frame: Baseline and Week 24
Percentage of Participants Who Achieve an American College of Rheumatology (ACR) 70 Response at Week 24
ACR 70 response was defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Time frame: Week 24
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16
ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Time frame: Week 16
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline and Week 24
Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline
Enthesitis was assessed using the Leeds Enthesitis Index (LEI), a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI greater than (\>) 0.
Time frame: Week 24
Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicates improvement of enthesitis.
Time frame: Baseline and Week 24
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) Score at Week 24
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline and Week 24
Percentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.
Time frame: Week 24
Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative change from baseline indicates improvement in dactylitis.
Time frame: Baseline and Week 24
Percentage of Participants Who Achieved ACR 20 Response by Visit Over Time Through Week 24
ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants Who Achieved ACR 50 Response by Visit Over Time Through Week 24
ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants Who Achieved ACR 70 Response by Visit Over Time Through Week 24
ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Weeks 4, 8, 12, 16, 20 and 24
ACR Components- Swollen Joint Count and Tender Joint Count Through Week 24
ACR components including swollen joint count (66 joints) and tender joint count (68 joints) were measured.
Time frame: Weeks 4, 8, 12, 16, 20 and 24
ACR Components- Patient's Assessment of Pain, Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity Through Week 24
ACR components included patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment (PtGA) of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment (PGA) of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis).
Time frame: Weeks 4, 8, 12, 16, 20 and 24
ACR Component- C-reactive Protein (CRP) Through Week 24
ACR component including CRP was measured.
Time frame: Weeks 4, 8, 12, 16, 20 and 24
ACR Component- Patient's Assessment of Physical Function as Assessed by HAQ-DI Scale Score at Weeks 4, 8, 12, 16, 20 and 24
Patient's assessment of physical function was measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI). HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
Time frame: Weeks 4, 8, 12, 16, 20 and 24
Percent Change From Baseline in ACR Components at Weeks 4, 8, 12, 16, 20 and 24
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Change From Baseline in HAQ-DI Score at Weeks 4, 8, 12, 16, 20 and 24
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
Time frame: Baseline, Week 4, 8, 12, 16, 20 and 24
Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score by Visit Over Time Through Week 24 Among Participants With HAQ-DI Score >=0.35 at Baseline
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
Time frame: Week 4, 8, 12, 16, 20 and 24
Percentage of Participants Who Achieved a DAS28 (CRP) Response by Visit Over Time Through Week 24
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: less than or equal to (\<=) 3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.
Time frame: Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants Who Achieved a DAS28 (CRP) Remission by Visit Over Time Through Week 24
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS 28 (CRP) remission was defined as DAS 28 (CRP) value \<2.6 at the analysis visit.
Time frame: Week 4, 8, 12, 16, 20 and 24
Change From Baseline in DAS28 (CRP) Score at Weeks 4, 8, 12, 16, 20 and 24
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative change from baseline indicates improvement of arthritis.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) by Visit Over Time Through Week 24
The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) using VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.
Time frame: Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants Who Achieved Resolution of Enthesitis at Weeks 4, 8, 16, and 24 Among the Participants With Enthesitis at Baseline
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.
Time frame: Weeks 4, 8, 16, and 24
Change From Baseline in Enthesitis Score at Weeks 4, 8, 16 and 24 Among the Participants With Enthesitis at Baseline
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.
Time frame: Baseline, Weeks 4, 8, 16 and 24
Percentage of Participants With Resolution of Dactylitis by Visit Over Time Through Week 24 Among the Participants With Dactylitis at Baseline
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.
Time frame: Weeks 4, 8, 16 and 24
Change From Baseline in Dactylitis Score at Weeks 4, 8, 16 and 24 Among the Participants With Dactylitis at Baseline
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement in dactylitis.
Time frame: Baseline, Weeks 4, 8, 16 and 24
Change From Baseline in the Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 8, 16 and 24
PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a compositive score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0-6), tender dactylitis count (scoring each digit from 0-3 and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
Time frame: Baseline, Weeks 8, 16 and 24
Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score at Weeks 16 and 24
GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.
Time frame: Baseline, Weeks 16 and 24
Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 4, 8, 12, 16, 20 and 24
DAPSA assessed the joint domain of psoriatic arthritis (PsA) and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \<lower limit of quantification \[LLOQ\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10 centimeter \[cm\] VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 16 and 24
MDA was considered achieved if at least 5 of the following 7 criteria were met at the analysis visit: tender joint count \<=1; swollen joint count \<=1; psoriasis activity and severity index \<=1; patient's assessment of pain VAS score of \<=15; patient's global assessment of disease activity VAS (arthritis and psoriasis) score of \<=20; HAQ-DI \<=0.5; and tender entheseal points \<=1.
Time frame: Weeks 16 and Week 24
Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score Through Week 24 Among the Participants With Spondylitis and Peripheral Arthritis and BASDAI Score >0 at Baseline
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis with peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
Time frame: Weeks 8, 16 and 24
Change From Baseline in BASDAI Score at Week 8, 16, and Week 24 Among Participants With Spondylitis and Peripheral Arthritis at Baseline
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis with peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
Time frame: Baseline, Weeks 8, 16, and 24
Percentage of Participants With Low or Very Low Disease Activity Based on Psoriatic Arthritis Disease Activity Score (PASDAS) by Visit Over Time Through Week 24
PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a compositive score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0-6), tender dactylitis count (scoring each digit from 0-3 and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high).
Time frame: Weeks 8, 16 and 24
Percentage of Participants With Low Disease Activity Based on Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index by Visit Over Time Through Week 24
GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of the Desirability Function (AMDF), which was derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100= poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL =25.355 + \[2.367\*HAQ-DI\] - \[0.234\*SF-PCS\] - \[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0 to 100, higher scores= better quality of life) and SF-MCS (score ranges from 0 to 100, higher scores= better quality of life). The total score is from 0-10, where lower score indicates better response. Higher score indicates more active disease activity.
Time frame: Weeks 16 and 24
Percentage of Participants With Low Disease Activity or Remission Based on Disease Activity Index for Psoriatic Arthritis (DAPSA) by Visit Over Time Through Week 24
DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10 cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. The assessment does not have a score range with an upper or lower bound.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20 and 24
Percentage of Participants With Very Low Disease Activity (VLDA) by Visit Over Time Through Week 24
A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15; patient global disease activity VAS \[arthritis and psoriasis\] score of \<=20; Health Assessment Questionnaire (HAQ) score \<=0.5; and tender entheseal points \<=1) at that visit.
Time frame: Weeks 16 and 24
Percentage of Participants Who Achieved PASI 75 Response at Weeks 16 and 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 75 response: \>=75% improvement in PASI score from baseline.
Time frame: Weeks 16 and 24
Percentage of Participants Who Achieved PASI 90 Response at Weeks 16 and 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 90 response: \>=90% improvement in PASI score from baseline.
Time frame: Weeks 16 and 24
Percentage of Participants Who Achieved PASI 100 Response by Visit Over Time Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 100 response: 100% improvement in PASI score from baseline.
Time frame: Weeks 16 and 24
Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.
Time frame: Weeks 16 and 24
Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response by Visit Over Time Through Week 24 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.
Time frame: Weeks 16 and 24
Percentage of Participants With an IGA Score of 0 (Cleared) at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved IGA Score of 0 (cleared) at a specific timepoint and did not meet any TF criteria before, were considered as responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered as non-responders.
Time frame: Weeks 16 and 24
Change From Baseline in PASI Score at Weeks 16 and 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.
Time frame: Baseline, Weeks 16 and 24
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) at Weeks 8, 16 and 24
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline, Weeks 8, 16 and 24
Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) at Weeks 8, 16 and 24
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline, Weeks 8, 16 and 24
Change From Baseline in Norm Based Scores of SF-36 Scales at Weeks 8, 16 and 24
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline, Week 8, 16 and 24
Percentage of Participants Who Achieved >=5-point Improvement From Baseline in SF-36 MCS Score by Visit Over Time Through Week 24
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
Time frame: Weeks 8, 16 and 24
Percentage of Participants Who Achieved >=5 Point Improvement From Baseline in SF-36 PCS Score Through Week 24
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
Time frame: Weeks 8, 16 and 24
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 8, 16, and 24
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Time frame: Baseline, Weeks 8, 16 and 24
Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 8, 16, and 24
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Time frame: Weeks 8, 16, and 24
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Scores at Weeks 8, 16 and 24
PROMIS-29 contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 numeric rating scale (NRS). The raw score of each domain is converted into a standardized score with a mean of 50 and a standard deviation (SD) of 10 for the general population in the US (T-Score).
Time frame: Baseline, Weeks 8, 16 and 24
Change From Baseline in FACIT-Fatigue Score at Week 24 by ACR 20 Response at Week 24
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Time frame: Baseline and Week 24
Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Week 24 by ACR 20 Response at Week 24
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Time frame: Week 24
Percentage of Participants Who Achieved an Improvement of >=3 Points From Baseline in PROMIS-29 Domain Scores at Weeks 8, 16, and 24
PROMIS-29 contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).
Time frame: Weeks 8, 16, and 24
Percentage of Participants Who Achieved an Improvement of >=5 Points From Baseline in PROMIS-29 Domain Scores at Weeks 8, 16, and 24
PROMIS-29 contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).
Time frame: Weeks 8, 16, and 24
Percentage of Participants Who Achieved ACR 20 Response at Weeks 24, 28, 36, 44 and 52
ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Weeks 24, 28, 36, 44 and 52
Percentage of Participants Who Achieved ACR 50 Response at Weeks 24, 28, 36, 44 and 52
ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Weeks 24, 28, 36, 44 and 52
Percentage of Participants Who Achieved ACR 70 Response at Weeks 24, 28, 36, 44 and 52
ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Weeks 24, 28, 36, 44 and 52
Percent Change From Baseline in ACR Components at Weeks 24, 28, 36, 44 and 52
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
Time frame: Baseline, Weeks 24, 28, 36, 44 and 52
Change From Baseline in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
Time frame: Baseline, Weeks 24, 28, 36, 44 and 52
Percentage of Participants Who Achieved a Clinically Meaningful Improvement (>=0.35 Improvement From Baseline) in HAQ-DI Score at Weeks 24, 28, 36, 44 and 52 Among Participants With HAQ-DI Score >=0.35 at Baseline
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
Time frame: Weeks 24, 28, 36, 44 and 52
Change From Baseline in DAS28 (CRP) Score at Weeks 24, 28, 36, 44 and 52
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.
Time frame: Baseline, Weeks 24, 28, 36, 44 and 52
Percentage of Participants Who Achieved a DAS28 (CRP) Response at Weeks 24, 28, 36, 44 and 52
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.
Time frame: Weeks 24, 28, 36, 44 and 52
Percentage of Participants Who Achieved a DAS28 (CRP) Remission at Weeks 24, 28, 36, 44 and 52
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission was defined as DAS28 (CRP) value \<2.6 at the analysis visit.
Time frame: Weeks 24, 28, 36, 44 and 52
Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 24
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
Time frame: Week 52
Percentage of Participants Who Achieved a Response Based on Modified Psoriatic Arthritis Responder Criteria (PsARC) at Weeks 24, 28, 36, 44 and 52
The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.
Time frame: Weeks 24, 28, 36, 44 and 52
Change From Baseline in the Disease Activity Index for Psoriatic Arthritis (DAPSA) Score at Weeks 24, 28, 36, 44 and 52
DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.
Time frame: Baseline, Weeks 24, 28, 36, 44 and 52
Percentage of Participants Who Achieved Both PASI 75 and Modified PsARC Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.
Time frame: Weeks 24 and 52
Percentage of Participants Who Achieved Both PASI 75 and ACR 20 Responses at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in SJC (66 joints)+TJC (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.
Time frame: Weeks 24 and 52
Change From Baseline in PASI Score at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative changes from baseline indicate improvement of psoriasis.
Time frame: Baseline, Weeks 24 and 52
Percentage of Participants Who Achieved PASI 75 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline.
Time frame: Weeks 24 and 52
Percentage of Participants Who Achieved PASI 90 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \>=90% improvement in PASI score from baseline.
Time frame: Weeks 24 and 52
Percentage of Participants Who Achieved PASI 100 Response at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.
Time frame: Weeks 24 and 52
Percentage of Participants Who Achieved >=5 Point Improvement From Baseline in SF-36 PCS Score at Weeks 24, 36 and 52
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
Time frame: Weeks 24, 36 and 52
Percentage of Participants Who Achieved >=5 Point Improvement From Baseline in SF-36 MCS Score at Weeks 24, 36 and 52
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
Time frame: Weeks 24, 36 and 52
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Weeks 24 and 52
MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).
Time frame: Weeks 24 and 52
Change From Baseline in Group of Research and Assessment of Psoriasis and Psoriatic Arthritis Composite (GRACE) Score Index at Weeks 24 and 52
GRACE index is a composite PsA disease activity score converted from AMDF, which was derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100= poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL =25.355 + \[2.367\*HAQ-DI\] - \[0.234\*SF-PCS\] - \[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0 to 100, higher scores= better quality of life) and SF-MCS (score ranges from 0 to 100, higher scores= better quality of life). The total score is from 0-10, where lower score indicates better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.
Time frame: Baseline, Weeks 24 and 52
Change From Baseline in Psoriatic Arthritis Disease Activity (PASDAS) Score at Weeks 24 and 52
PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a compositive score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0-6), tender dactylitis count (scoring each digit from 0-3 and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
Time frame: Baseline, Weeks 24 and 52
Percentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 24
ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Week 52
Percentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 24
ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Week 52
Percentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 24
ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
Time frame: Week 52
Percentage of Participants Who Achieved >= 20%, >=50%, >=70%, and >=90% Improvement From Baseline in BASDAI Score at Weeks 24 and 52 Among Participants With Spondylitis and Peripheral Arthritis as Their Primary Arthritic Presentation of PsA
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis with peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
Time frame: Weeks 24 and 52
Percentage of Participants With Resolution of Enthesitis at Weeks 24, 36, 44 and 52 Among the Participants With Enthesitis at Baseline
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.
Time frame: Weeks 24, 36, 44 and 52
Percentage of Participants With Resolution of Dactylitis at Weeks 24, 36, 44 and 52 Among Participants With Dactylitis at Baseline
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.
Time frame: Weeks 24, 36, 44 and 52
Change From Baseline in Enthesitis Score (Based on SPARCC) at Weeks 24, 36, 44 and 52 Among the Participants With Enthesitis at Baseline
Enthesitis was assessed using the Spondyloarthritis Research Consortium of Canada (SPARCC). The SPARCC developed a measure for enthesitis in general spondyloarthritis which evaluates the presence or absence of pain by applying local pressure to the following entheses: supraspinatus insertion (left and right), medial epicondyle humerus (left and right), lateral epicondyle humerus (left and right), greater trochanter (left and right), quadriceps-to-patella (left and right), patellar-tibia (left and right), achilles tendon insertion (left and right), plantar fascia (left and right). Tenderness on examination was recorded as either present (1) or absent (0) for each of the 16 sites for an overall score range of 0-16. Higher scores indicate more severe enthesitis. Negative changes from baseline indicate improvement of enthesitis.
Time frame: Baseline, Weeks 24, 36, 44 and 52
Change From Baseline in Enthesitis Score (Based on LEI) at Weeks 24, 36, 44 and 52 Among the Participants With Enthesitis at Baseline
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.
Time frame: Baseline, Weeks 24, 36, 44 and 52
Change From Baseline in Dactylitis Score at Weeks 24, 36, 44 and 52 Among the Participants With Dactylitis at Baseline
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement in dactylitis.
Time frame: Baseline, Weeks 24, 36, 44 and 52
Percentage of Participants With an IGA Score of 0 (Cleared) or 1 (Cleared) at Weeks 24 and 52 Among Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 at Baseline
A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Time frame: Weeks 24 and 52
Change From Baseline in SF-36 Physical Component Summary (PCS) Score at Weeks 24, 36 and 52
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline, Weeks 24, 36 and 52
Change From Baseline in SF-36 Mental Component Summary (MCS) Score at Weeks 24, 36 and 52
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline, Weeks 24, 36 and 52
Change From Baseline in Norm Based Scores of SF-36 Scales at Week 24, 36 and 52
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
Time frame: Baseline, Weeks 24, 36 and 52
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 24, 36 and 52
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Time frame: Baseline, Weeks 24, 36 and 52
Percentage of Participants Who Achieved >=4-point Improvement From Baseline in FACIT-Fatigue Score at Weeks 24, 36 and 52
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
Time frame: Weeks 24, 36 and 52
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Scores at Weeks 24, 36 and 52
PROMIS-29 contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).
Time frame: Baseline, Weeks 24, 36 and 52
A total of 383 participants were enrolled. Among them, 381 participants received at least one dose of study drug (126 in placebo group, 127 in guselkumab 100 mg q8w group and 128 in guselkumab 100 mg q4w group). One participant was randomized to guselkumab 100 mg q8w but not treated.
| Milestone | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Started | 126 | 127 | 128 |
| Completed | 114 | 123 | 125 |
| Not completed | 12 | 4 | 3 |
| Withdrew: Other | 0 | 1 | 1 |
| Withdrew: Initiated prohibited medication | 1 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 1 |
| Withdrew: Lack of efficacy | 4 | 0 | 0 |
| Withdrew: Adverse event | 2 | 3 | 1 |
| Milestone | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Started | 114 | 123 | 125 |
| Completed | 107 | 116 | 124 |
| Not completed | 7 | 7 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 |
| Withdrew: Lack of efficacy | 4 | 3 | 1 |
| Withdrew: Adverse event | 3 | 2 | 0 |
| Milestone | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Started | 107 | 116 | 124 |
| Completed | 106 | 114 | 123 |
| Not completed | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 | 1 |
ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP. Treatment Failure (TF) criteria- discontinued study drug, initiated/increased dose of non-biologic disease-modifying antirheumatic drugs (DMARDs) or oral corticosteroids, initiated prohibited psoriatic arthritis treatment.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 | 22.2 | 52.0 | 59.4 |
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 24 | -0.0743 (-0.1605 to 0.0119) | -0.3225 (-0.4082 to -0.2369) | -0.3968 (-0.4825 to -0.3112) |
ACR 50 response was defined as greater than or equal to (\>=)50 percent (%) improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and C-Reactive Protein (CRP).
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 24 | 8.7 | 29.9 | 35.9 |
A psoriasis Investigator's Global Assessment (IGA) response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>=2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants With Psoriasis Response of IGA (Score: 0[Cleared] or 1[Minimal] and >=2 Grade Reduction From Baseline) at Week 24 Among Participants With >=3% Body Surface Area (BSA) Psoriatic Involvement and IGA Score of >=2 (Mild) at Baseline | 15.4 | 57.3 | 75.3 |
ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform task in that area), and C-reactive protein (CRP).
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 16 | 25.4 | 52.0 | 60.2 |
The Disease Activity Index Score (DAS28) based on C-Reactive Protein (CRP) is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in Disease Activity Score (DAS28) (C-reactive Protein [CRP]) Score at Week 24 | -0.70 (-0.89 to -0.51) | -1.43 (-1.61 to -1.24) | -1.61 (-1.80 to -1.42) |
ACR 70 response was defined as \>= 70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieve an American College of Rheumatology (ACR) 70 Response at Week 24 | 5.6 | 11.8 | 20.3 |
ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 50 Response at Week 16 | 12.7 | 22.8 | 26.6 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24 | 1.96 (0.69 to 3.24) | 6.10 (4.83 to 7.37) | 6.87 (5.60 to 8.14) |
Enthesitis was assessed using the Leeds Enthesitis Index (LEI), a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI greater than (\>) 0.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants With Resolution of Enthesitis at Week 24 Among the Participants With Enthesitis at Baseline | 27.3 | 40.3 | 47.9 |
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicates improvement of enthesitis.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in Enthesitis Score (Based on LEI) at Week 24 Among the Participants With Enthesitis at Baseline | -1.01 (-1.37 to -0.66) | -1.35 (-1.72 to -0.98) | -1.75 (-2.13 to -1.38) |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in 36-Item Short Form Health Survey (SF-36) Mental Component Summary (MCS) Score at Week 24 | 2.37 (0.93 to 3.81) | 3.20 (1.78 to 4.63) | 3.60 (2.17 to 5.02) |
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Percentage of Participants With Resolution of Dactylitis at Week 24 Among the Participants With Dactylitis at Baseline | 49.1 | 65.3 | 63.2 |
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative change from baseline indicates improvement in dactylitis.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Change From Baseline in Dactylitis Scores at Week 24 Among the Participants With Dactylitis at Baseline | -4.30 (-5.96 to -2.63) | -6.11 (-7.81 to -4.41) | -5.82 (-7.82 to -3.83) |
ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4 | 7.9 | 15.7 | 20.3 |
| Week 8 | 18.3 | 36.2 | 39.1 |
| Week 12 | 27.0 | 43.3 | 53.1 |
| Week 16 | 25.4 | 52.0 | 60.2 |
| Week 20 | 30.2 | 51.2 | 62.5 |
| Week 24 | 22.2 | 52.0 | 59.4 |
ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4 | 2.4 | 1.6 | 3.1 |
| Week 8 | 7.9 | 7.9 | 10.9 |
| Week 12 | 10.3 | 20.5 | 24.2 |
| Week 16 | 12.7 | 22.8 | 26.6 |
| Week 20 | 13.5 | 29.1 | 37.5 |
| Week 24 | 8.7 | 29.9 | 35.9 |
ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4 | 0 | 0.8 | 0 |
| Week 8 | 1.6 | 3.1 | 2.3 |
| Week 12 | 4.8 | 7.1 | 6.3 |
| Week 16 | 5.6 | 7.9 | 7.8 |
| Week 20 | 7.1 | 11.8 | 17.2 |
| Week 24 | 5.6 | 11.8 | 20.3 |
ACR components including swollen joint count (66 joints) and tender joint count (68 joints) were measured.
| joints | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4: Swollen Joint Count | 8.0 ± 7.71 | 7.7 ± 7.89 | 5.7 ± 4.89 |
| Week 8: Swollen Joint Count | 6.6 ± 5.83 | 6.2 ± 9.36 | 4.4 ± 5.22 |
| Week 12: Swollen Joint Count | 6.1 ± 6.41 | 4.5 ± 6.63 | 3.5 ± 5.60 |
| Week 16: Swollen Joint Count | 5.9 ± 6.09 | 3.8 ± 5.15 | 2.7 ± 4.25 |
| Week 20: Swollen Joint Count | 5.2 ± 5.72 | 4.0 ± 6.28 | 2.7 ± 4.87 |
| Week 24: Swollen Joint Count | 4.9 ± 6.14 | 3.8 ± 6.53 | 2.8 ± 5.27 |
| Week 4: Tender Joint Count | 17.0 ± 13.81 | 16.3 ± 14.11 | 14.4 ± 11.85 |
| Week 8: Tender Joint Count | 15.8 ± 13.68 | 13.5 ± 13.86 | 12.2 ± 11.53 |
| Week 12: Tender Joint Count | 15.1 ± 14.21 | 11.5 ± 13.16 | 9.7 ± 11.14 |
| Week 16: Tender Joint Count | 15.5 ± 13.61 | 10.3 ± 12.06 | 9.0 ± 10.29 |
| Week 20: Tender Joint Count | 13.4 ± 13.02 | 9.9 ± 12.53 | 7.9 ± 9.54 |
| Week 24: Tender Joint Count | 13.2 ± 12.09 | 9.9 ± 12.82 | 8.4 ± 10.47 |
ACR components included patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment (PtGA) of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment (PGA) of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis).
| millimeters | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4: Patient's Assessment of Pain | 5.74 ± 2.296 | 5.49 ± 2.159 | 5.18 ± 2.224 |
| Week 8: Patient's Assessment of Pain | 5.06 ± 2.257 | 4.90 ± 2.310 | 4.54 ± 2.397 |
| Week 12: Patient's Assessment of Pain | 4.96 ± 2.355 | 4.35 ± 2.503 | 4.09 ± 2.346 |
| Week 16: Patient's Assessment of Pain | 5.01 ± 2.417 | 4.25 ± 2.471 | 3.85 ± 2.462 |
| Week 20: Patient's Assessment of Pain | 4.98 ± 2.497 | 4.00 ± 2.481 | 3.51 ± 2.409 |
| Week 24: Patient's Assessment of Pain | 5.09 ± 2.379 | 3.82 ± 2.470 | 3.52 ± 2.502 |
| Week 4: PtGA of Disease Activity | 5.86 ± 2.281 | 5.80 ± 2.181 | 5.36 ± 2.200 |
| Week 8: PtGA of Disease Activity | 5.26 ± 2.271 | 4.99 ± 2.381 | 4.82 ± 2.384 |
| Week 12: PtGA of Disease Activity | 5.13 ± 2.398 | 4.46 ± 2.459 | 4.18 ± 2.441 |
| Week 16: PtGA of Disease Activity | 5.12 ± 2.379 | 4.59 ± 2.541 | 3.96 ± 2.458 |
| Week 20: PtGA of Disease Activity | 5.08 ± 2.596 | 4.21 ± 2.604 | 3.57 ± 2.443 |
| Week 24: PtGA of Disease Activity | 5.19 ± 2.419 | 4.03 ± 2.603 | 3.48 ± 2.412 |
| Week 4: PGA of Disease Activity | 5.53 ± 1.986 | 4.94 ± 1.977 | 4.72 ± 1.955 |
| Week 8: PGA of Disease Activity | 4.79 ± 2.197 | 3.88 ± 2.299 | 3.63 ± 2.035 |
| Week 12: PGA of Disease Activity | 4.31 ± 2.196 | 3.47 ± 1.992 | 3.08 ± 2.031 |
| Week 16: PGA of Disease Activity | 4.31 ± 2.296 | 3.39 ± 2.260 | 2.73 ± 2.022 |
| Week 20: PGA of Disease Activity | 3.96 ± 2.367 | 2.90 ± 2.132 | 2.44 ± 1.780 |
| Week 24: PGA of Disease Activity | 4.07 ± 2.361 | 2.81 ± 2.169 | 2.34 ± 1.889 |
ACR component including CRP was measured.
| milligrams per deciliter (mg/dL) | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4 | 1.220 ± 1.5753 | 1.159 ± 1.7641 | 0.785 ± 1.1917 |
| Week 8 | 1.184 ± 1.8722 | 1.059 ± 1.4736 | 0.720 ± 1.2637 |
| Week 12 | 1.138 ± 1.5889 | 0.936 ± 1.3470 | 0.629 ± 0.7882 |
| Week 16 | 1.143 ± 1.6005 | 0.996 ± 1.5296 | 0.592 ± 0.7861 |
| Week 20 | 1.105 ± 1.6401 | 0.941 ± 1.5067 | 0.592 ± 0.8831 |
| Week 24 | 1.319 ± 3.0033 | 0.894 ± 1.5386 | 0.633 ± 1.0522 |
Patient's assessment of physical function was measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI). HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4 | 1.2188 ± 0.67806 | 1.1371 ± 0.59755 | 0.9824 ± 0.65278 |
| Week 8 | 1.1331 ± 0.66928 | 1.0188 ± 0.61463 | 0.9150 ± 0.65488 |
| Week 12 | 1.1169 ± 0.63813 | 0.9831 ± 0.64058 | 0.8012 ± 0.63060 |
| Week 16 | 1.1035 ± 0.65372 | 0.9375 ± 0.65845 | 0.7776 ± 0.66011 |
| Week 20 | 1.1049 ± 0.67838 | 0.8730 ± 0.62347 | 0.7619 ± 0.66491 |
| Week 24 | 1.1133 ± 0.69279 | 0.8770 ± 0.60691 | 0.7264 ± 0.63225 |
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
| percent change | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4: Swollen Joint Count | -22.4 ± 49.78 | -27.5 ± 42.92 | -29.3 ± 50.85 |
| Week 8: Swollen Joint Count | -29.4 ± 50.57 | -45.3 ± 66.29 | -46.5 ± 53.81 |
| Week 12: Swollen Joint Count | -38.1 ± 55.69 | -60.0 ± 48.23 | -61.1 ± 42.62 |
| Week 16: Swollen Joint Count | -36.6 ± 56.25 | -65.8 ± 40.42 | -71.3 ± 34.69 |
| Week 20: Swollen Joint Count | -44.4 ± 54.01 | -66.2 ± 38.24 | -71.0 ± 40.88 |
| Week 24: Swollen Joint Count | -49.5 ± 45.66 | -66.6 ± 47.09 | -73.3 ± 37.95 |
| Week 4: Tender Joint Count | -15.4 ± 36.11 | -22.2 ± 36.99 | -17.2 ± 50.26 |
| Week 8: Tender Joint Count | -21.4 ± 41.36 | -35.7 ± 47.45 | -31.4 ± 47.13 |
| Week 12: Tender Joint Count | -24.5 ± 50.74 | -48.0 ± 40.24 | -47.9 ± 38.76 |
| Week 16: Tender Joint Count | -19.9 ± 50.84 | -52.6 ± 36.33 | -49.2 ± 57.97 |
| Week 20: Tender Joint Count | -30.8 ± 53.79 | -55.4 ± 40.17 | -59.4 ± 35.91 |
| Week 24: Tender Joint Count | -29.1 ± 53.54 | -53.7 ± 45.12 | -56.0 ± 41.76 |
| Week 4: Patient's Assessment of Pain | 2.98 ± 38.337 | -2.41 ± 43.139 | -9.12 ± 37.068 |
| Week 8: Patient's Assessment of Pain | -7.41 ± 42.846 | -12.18 ± 46.920 | -19.41 ± 45.862 |
| Week 12: Patient's Assessment of Pain | -7.82 ± 49.910 | -22.74 ± 45.048 | -27.28 ± 42.305 |
| Week 16: Patient's Assessment of Pain | -7.86 ± 47.980 | -25.45 ± 47.860 | -29.74 ± 53.817 |
| Week 20: Patient's Assessment of Pain | -8.31 ± 54.287 | -29.36 ± 46.581 | -38.45 ± 46.235 |
| Week 24: Patient's Assessment of Pain | -5.35 ± 53.599 | -32.65 ± 45.343 | -38.97 ± 43.873 |
| Week 4: PtGA of Disease Activity | 0.06 ± 37.022 | -9.57 ± 30.374 | -2.82 ± 58.438 |
| Week 8: PtGA of Disease Activity | -9.06 ± 43.197 | -20.08 ± 45.707 | -14.95 ± 46.672 |
| Week 12: PtGA of Disease Activity | -10.00 ± 49.346 | -28.38 ± 40.863 | -26.84 ± 48.800 |
| Week 16: PtGA of Disease Activity | -8.56 ± 55.279 | -26.93 ± 42.999 | -30.16 ± 47.486 |
| Week 20: PtGA of Disease Activity | -11.67 ± 54.531 | -34.61 ± 40.905 | -38.76 ± 43.118 |
| Week 24: PtGA of Disease Activity | -4.91 ± 65.728 | -37.16 ± 39.760 | -40.32 ± 42.037 |
| Week 4: PGA of Disease Activity | -10.50 ± 30.144 | -17.83 ± 34.370 | -22.42 ± 34.627 |
| Week 8: PGA of Disease Activity | -20.87 ± 38.908 | -36.57 ± 34.906 | -41.05 ± 31.682 |
| Week 12: PGA of Disease Activity | -30.47 ± 32.894 | -40.61 ± 37.367 | -48.87 ± 35.082 |
| Week 16: PGA of Disease Activity | -29.42 ± 36.058 | -45.04 ± 36.363 | -55.36 ± 32.848 |
| Week 20: PGA of Disease Activity | -36.48 ± 35.490 | -51.88 ± 34.491 | -59.57 ± 30.353 |
| Week 24: PGA of Disease Activity | -33.95 ± 34.349 | -53.43 ± 37.305 | -61.39 ± 31.234 |
| Week 4: HAQ-DI Score | 4.3521 ± 61.86548 | -0.4964 ± 54.63888 | -5.9245 ± 53.44204 |
| Week 8: HAQ-DI Score | -3.3329 ± 48.15101 | -9.1556 ± 65.76295 | -11.3467 ± 69.07565 |
| Week 12: HAQ-DI Score | -2.1600 ± 88.42239 | -13.1115 ± 69.57297 | -21.6242 ± 65.32053 |
| Week 16: HAQ-DI Score | -3.2447 ± 109.78825 | -19.5421 ± 55.80512 | -27.7444 ± 68.28273 |
| Week 20: HAQ-DI Score | -10.5259 ± 44.67386 | -23.6139 ± 65.27566 | -26.2478 ± 74.38446 |
| Week 24: HAQ-DI Score | -7.3745 ± 61.62081 | -8.7950 ± 148.19861 | -31.1750 ± 72.70079 |
| Week 4: CRP | 9.972 ± 66.9599 | -4.060 ± 76.1801 | -1.054 ± 102.5692 |
| :Week 8: CRP | 10.402 ± 83.4766 | 5.403 ± 111.6889 | 11.791 ± 273.1510 |
| Week 12: CRP | 9.295 ± 94.9020 | -2.507 ± 98.4549 | -7.908 ± 114.4983 |
| Week 16: CRP | 82.057 ± 734.6577 | 7.139 ± 134.6682 | 2.759 ± 208.7305 |
| Week 20: CRP | 5.768 ± 98.6914 | -11.151 ± 84.9807 | -14.684 ± 98.0041 |
| Week 24: CRP | 31.628 ± 239.7722 | -7.404 ± 101.4807 | -6.112 ± 148.2088 |
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4 | 0.0043 (-0.0562 to 0.0647) | -0.0571 (-0.1173 to 0.0031) | -0.1095 (-0.1695 to -0.0494) |
| Week 8 | -0.0781 (-0.1498 to -0.0064) | -0.1711 (-0.2423 to -0.0999) | -0.1907 (-0.2619 to -0.1194) |
| Week 12 | -0.1013 (-0.1783 to -0.0243) | -0.2174 (-0.2938 to -0.1410) | -0.3209 (-0.3973 to -0.2444) |
| Week 16 | -0.1131 (-0.1955 to -0.0307) | -0.2620 (-0.3438 to -0.1802) | -0.3393 (-0.4211 to -0.2575) |
| Week 20 | -0.1079 (-0.1935 to -0.0223) | -0.3293 (-0.4143 to -0.2443) | -0.3708 (-0.4558 to -0.2858) |
| Week 24 | -0.0743 (-0.1605 to -0.0119) | -0.3225 (-0.4082 to -0.2369) | -0.3968 (-0.4825 to -0.3112) |
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3, where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4 | 20.0 | 26.8 | 30.9 |
| Week 8 | 25.5 | 40.2 | 38.2 |
| Week 12 | 27.3 | 45.5 | 51.8 |
| Week 16 | 30.9 | 46.4 | 57.3 |
| Week 20 | 28.2 | 50.9 | 56.4 |
| Week 24 | 29.1 | 50.9 | 57.3 |
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: less than or equal to (\<=) 3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4 | 27.0 | 33.1 | 40.6 |
| Week 8 | 35.7 | 59.1 | 54.7 |
| Week 12 | 41.3 | 67.7 | 74.2 |
| Week 16 | 44.4 | 65.4 | 73.4 |
| Week 20 | 46.0 | 66.1 | 75.0 |
| Week 24 | 44.4 | 70.9 | 76.6 |
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS 28 (CRP) remission was defined as DAS 28 (CRP) value \<2.6 at the analysis visit.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4 | 3.2 | 7.9 | 7.8 |
| Week 8 | 7.9 | 11.0 | 11.7 |
| Week 12 | 9.5 | 22.0 | 21.9 |
| Week 16 | 7.9 | 19.7 | 25.0 |
| Week 20 | 17.5 | 25.2 | 36.7 |
| Week 24 | 12.7 | 23.6 | 35.9 |
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative change from baseline indicates improvement of arthritis.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4 | -0.35 (-0.48 to -0.22) | -0.53 (-0.67 to -0.40) | -0.56 (-0.69 to -0.43) |
| Week 8 | -0.55 (-0.71 to -0.39) | -0.83 (-0.99 to -0.67) | -0.88 (-1.04 to -0.72) |
| Week 12 | -0.63 (-0.80 to -0.47) | -1.16 (-1.33 to -0.99) | -1.23 (-1.39 to -1.06) |
| Week 16 | -0.64 (-0.82 to -0.46) | -1.19 (-1.37 to -1.01) | -1.38 (-1.56 to -1.20) |
| Week 20 | -0.80 (-1.00 to -0.60) | -1.38 (-1.58 to -1.19) | -1.56 (-1.76 to -1.37) |
| Week 24 | -0.70 (-0.89 to -0.51) | -1.43 (-1.61 to -1.24) | -1.61 (-1.80 to -1.42) |
The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) using VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4 | 20.6 | 29.1 | 33.6 |
| Week 8 | 32.5 | 56.7 | 48.4 |
| Week 12 | 41.3 | 58.3 | 66.4 |
| Week 16 | 36.5 | 64.6 | 68.0 |
| Week 20 | 41.3 | 66.1 | 75.8 |
| Week 24 | 31.0 | 59.8 | 72.7 |
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4 | 22.1 | 18.1 | 27.4 |
| Week 8 | 23.4 | 30.6 | 30.1 |
| Week 16 | 37.7 | 34.7 | 45.2 |
| Week 24 | 27.3 | 40.3 | 47.9 |
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4 | -0.37 (-0.69 to -0.05) | -0.45 (-0.78 to -0.11) | -0.96 (-1.30 to -0.62) |
| Week 8 | -0.65 (-1.00 to -0.31) | -0.83 (-1.19 to -0.47) | -1.11 (-1.48 to -0.74) |
| Week 16 | -0.99 (-1.36 to -0.61) | -1.00 (-1.39 to -0.61) | -1.51 (-1.90 to -1.11) |
| Week 24 | -1.01 (-1.37 to -0.66) | -1.35 (-1.72 to -0.98) | -1.75 (-2.13 to -1.38) |
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4 | 41.8 | 34.7 | 31.6 |
| Week 8 | 41.8 | 40.8 | 44.7 |
| Week 16 | 43.6 | 59.2 | 57.9 |
| Week 24 | 49.1 | 65.3 | 63.2 |
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement in dactylitis.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4 | -2.77 (-4.24 to -1.30) | -2.24 (-3.76 to -0.72) | -2.63 (-4.39 to -0.86) |
| Week 8 | -2.92 (-4.58 to -1.26) | -4.00 (-5.72 to -2.29) | -3.92 (-5.90 to -1.93) |
| Week 16 | -4.03 (-5.76 to -2.30) | -6.00 (-7.79 to -4.22) | -6.29 (-8.36 to -4.22) |
| Week 24 | -4.30 (-5.96 to -2.63) | -6.11 (-7.81 to -4.41) | -5.82 (-7.82 to -3.83) |
PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a compositive score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0-6), tender dactylitis count (scoring each digit from 0-3 and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | -0.759 (-0.961 to -0.556) | -1.315 (-1.518 to -1.113) | -1.428 (-1.628 to -1.228) |
| Week 16 | -0.980 (-1.221 to -0.739) | -1.779 (-2.019 to -1.539) | -2.083 (-2.322 to -1.843) |
| Week 24 | -0.959 (-1.212 to -0.707) | -2.124 (-2.376 to -1.871) | -2.407 (-2.657 to -2.156) |
GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of Desirability Function (AMDF), derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100=poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL=25.355 + \[2.367\*HAQ-DI\]-\[0.234\*SF-PCS\]-\[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0-100, higher scores= better quality of life) and SF-MCS (score ranges from 0-100, higher scores= better quality of life). Total score is from 0-10, lower score=better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | -0.918 (-1.176 to -0.659) | -2.024 (-2.283 to -1.765) | -2.368 (-2.625 to -2.111) |
| Week 24 | -0.854 (-1.122 to -0.586) | -2.368 (-2.636 to -2.099) | -2.735 (-3.001 to -2.468) |
DAPSA assessed the joint domain of psoriatic arthritis (PsA) and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL, value \<lower limit of quantification \[LLOQ\] is considered equal to half of the value of LLOQ for numerical calculations), patient assessment of pain (0-10 centimeter \[cm\] VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 4 | -4.826 (-6.901 to -2.752) | -7.815 (-9.926 to -5.705) | -8.574 (-10.636 to -6.511) |
| Week 8 | -8.776 (-11.307 to -6.246) | -13.601 (-16.118 to -11.084) | -13.231 (-15.731 to -10.732) |
| Week 12 | -10.135 (-12.670 to -7.599) | -18.167 (-20.704 to -15.631) | -17.433 (-19.949 to -14.918) |
| Week 16 | -9.964 (-12.568 to -7.359) | -19.830 (-22.426 to -17.234) | -19.389 (-21.977 to -16.802) |
| Week 20 | -11.552 (-14.228 to -8.876) | -20.570 (-23.248 to -17.891) | -21.244 (-23.903 to -18.586) |
| Week 24 | -10.749 (-13.396 to -8.102) | -21.332 (-23.977 to -18.688) | -20.621 (-23.251 to -17.992) |
MDA was considered achieved if at least 5 of the following 7 criteria were met at the analysis visit: tender joint count \<=1; swollen joint count \<=1; psoriasis activity and severity index \<=1; patient's assessment of pain VAS score of \<=15; patient's global assessment of disease activity VAS (arthritis and psoriasis) score of \<=20; HAQ-DI \<=0.5; and tender entheseal points \<=1.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 7.1 | 15.7 | 18.0 |
| Week 24 | 11.1 | 22.8 | 30.5 |
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis with peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8: Participants with >=20% Improvement | 26.1 | 58.3 | 55.0 |
| Week 16: Participants with >=20% Improvement | 52.2 | 75.0 | 65.0 |
| Week 24: Participants with >=20% Improvement | 26.1 | 70.8 | 65.0 |
| Week 8: Participants with >=50% Improvement | 4.3 | 25.0 | 25.0 |
| Week 16: Participants with >=50% Improvement | 26.1 | 29.2 | 35.0 |
| Week 24: Participants with >=50% Improvement | 13.0 | 41.7 | 35.0 |
| Week 8: Participants with >=70% Improvement | 4.3 | 4.2 | 15.0 |
| Week 16: Participants with >=70% Improvement | 8.7 | 25.0 | 15.0 |
| Week 24: Participants with >=70% Improvement | 8.7 | 29.2 | 5.0 |
| Week 8: Participants with >=90% Improvement | 0 | 0 | 0 |
| Week 16: Participants with >=90% Improvement | 0 | 8.3 | 10.0 |
| Week 24: Participants with >=90% Improvement | 0 | 16.7 | 0 |
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis with peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | -0.595 (-1.351 to -0.162) | -1.577 (-2.296 to -0.859) | -1.976 (-2.779 to -1.174) |
| Week 16 | -1.604 (-2.483 to -0.725) | -2.419 (-3.261 to -1.577) | -2.469 (-3.405 to -1.533) |
| Week 24 | -0.919 (-1.795 to -0.043) | -2.665 (-3.503 to -1.826) | -2.074 (-3.006 to -1.142) |
PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a compositive score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0-6), tender dactylitis count (scoring each digit from 0-3 and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high).
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | 4.0 | 10.2 | 14.8 |
| Week 16 | 8.7 | 22.0 | 27.3 |
| Week 24 | 11.1 | 30.7 | 36.7 |
GRACE index is a composite PsA disease activity score converted from Arithmetic Mean of the Desirability Function (AMDF), which was derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100= poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL =25.355 + \[2.367\*HAQ-DI\] - \[0.234\*SF-PCS\] - \[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0 to 100, higher scores= better quality of life) and SF-MCS (score ranges from 0 to 100, higher scores= better quality of life). The total score is from 0-10, where lower score indicates better response. Higher score indicates more active disease activity.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 10.3 | 22.0 | 28.9 |
| Week 24 | 11.9 | 30.7 | 42.2 |
DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10 cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. The assessment does not have a score range with an upper or lower bound.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Baseline | 1.6 | 2.4 | 0.8 |
| Week 4 | 10.3 | 8.7 | 13.3 |
| Week 8 | 13.5 | 17.3 | 25.0 |
| Week 12 | 18.3 | 27.6 | 37.5 |
| Week 16 | 13.5 | 29.9 | 36.7 |
| Week 20 | 22.2 | 37.8 | 46.1 |
| Week 24 | 16.7 | 40.9 | 49.2 |
A measurement that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved VLDA at a visit if the participant fulfilled all 7 criteria (tender joint count \<=1; swollen joint count \<=1; PASI \<=1; patient pain VAS score of \<=15; patient global disease activity VAS \[arthritis and psoriasis\] score of \<=20; Health Assessment Questionnaire (HAQ) score \<=0.5; and tender entheseal points \<=1) at that visit.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 2.4 | 3.1 | 3.1 |
| Week 24 | 1.6 | 3.9 | 9.4 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 75 response: \>=75% improvement in PASI score from baseline.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 20.5 | 63.4 | 73.0 |
| Week 24 | 14.1 | 75.6 | 86.5 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 90 response: \>=90% improvement in PASI score from baseline.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 10.3 | 45.1 | 52.8 |
| Week 24 | 11.5 | 50.0 | 62.9 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 100 response: 100% improvement in PASI score from baseline.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 7.7 | 23.2 | 32.6 |
| Week 24 | 6.4 | 25.6 | 44.9 |
In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in swollen joint count (SJC) (66 joints) + tender joint count (TJC) (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 6.4 | 35.4 | 48.3 |
| Week 24 | 6.4 | 40.2 | 52.8 |
In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 9.0 | 48.8 | 55.1 |
| Week 24 | 5.1 | 50.0 | 62.9 |
The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4). Participants who achieved IGA Score of 0 (cleared) at a specific timepoint and did not meet any TF criteria before, were considered as responders at that time point. Participants who met 1 or more TF criteria before or with missing data at that time point were considered as non-responders.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | 9.0 | 32.9 | 40.4 |
| Week 24 | 7.7 | 37.8 | 53.9 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative change from baseline indicates improvement of psoriasis.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 16 | -2.910 (-4.207 to -1.612) | -9.631 (-10.881 to -8.381) | -10.096 (-11.318 to -8.874) |
| Week 24 | -2.317 (-3.709 to -0.926) | -9.974 (-11.323 to -8.624) | -10.915 (-12.224 to -9.605) |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | 2.15 (1.06 to 3.23) | 2.87 (1.80 to 3.95) | 4.46 (3.39 to 5.54) |
| Week 16 | 2.50 (1.31 to 3.69) | 5.26 (4.08 to 6.43) | 6.72 (5.54 to 7.89) |
| Week 24 | 1.96 (0.69 to 3.24) | 6.10 (4.83 to 7.37) | 6.87 (5.60 to 8.14) |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | 1.99 (0.73 to 3.24) | 2.72 (1.47 to 3.97) | 2.46 (1.22 to 3.71) |
| Week 16 | 2.25 (0.87 to 3.63) | 2.61 (1.25 to 3.98) | 3.04 (1.68 to 4.41) |
| Week 24 | 2.37 (0.93 to 3.81) | 3.20 (1.78 to 4.63) | 3.60 (2.17 to 5.02) |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8: Physical Function Score | 1.362 (0.201 to 2.524) | 2.616 (1.456 to 3.777) | 4.082 (2.927 to 5.237) |
| Week 16: Physical Function Score | 1.901 (0.603 to 3.199) | 5.143 (3.851 to 6.434) | 6.190 (4.902 to 7.478) |
| Week 24: Physical Function Score | 1.636 (0.249 to 3.023) | 5.776 (4.394 to 7.158) | 6.952 (5.571 to 8.333) |
| Week 8: Role-physical Score | 2.212 (1.104 to 3.321) | 2.084 (0.978 to 3.190) | 3.834 (2.730 to 4.938) |
| Week 16: Role-physical Score | 2.242 (1.037 to 3.447) | 4.224 (3.027 to 5.422) | 5.447 (4.250 to 6.644) |
| Week 24: Role-physical Score | 2.319 (1.063 to 3.576) | 4.878 (3.627 to 6.130) | 5.442 (4.189 to 6.694) |
| Week 8: Bodily Pain Score | 3.081 (1.876 to 4.286) | 3.886 (2.682 to 5.089) | 5.140 (3.941 to 6.338) |
| Week 16: Bodily Pain Score | 3.125 (1.859 to 4.391) | 5.059 (3.800 to 6.318) | 6.778 (5.521 to 8.035) |
| Week 24: Bodily Pain Score | 2.854 (1.468 to 4.240) | 6.840 (5.459 to 8.221) | 7.490 (6.110 to 8.871) |
| Week 8: General Health Score | 1.989 (0.806 to 3.172) | 3.071 (1.890 to 4.252) | 3.486 (2.309 to 4.663) |
| Week 16: General Health Score | 1.683 (0.492 to 2.874) | 3.769 (2.585 to 4.953) | 5.225 (4.042 to 6.408) |
| Week 24: General Health Score | 1.690 (0.510 to 2.869) | 4.349 (3.175 to 5.524) | 5.174 (3.998 to 6.349) |
| Week 8: Vitality Score | 2.312 (1.081 to 3.542) | 3.917 (2.689 to 5.144) | 4.614 (3.389 to 5.838) |
| Week 16: Vitality Score | 3.084 (1.720 to 4.449) | 4.777 (3.422 to 6.133) | 5.589 (4.234 to 6.943) |
| Week 24: Vitality Score | 2.311 (0.881 to 3.742) | 5.596 (4.172 to 7.020) | 6.426 (5.000 to 7.852) |
| Week 8: Social Function Score | 2.025 (0.643 to 3.407) | 3.287 (1.907 to 4.667) | 3.798 (2.423 to 5.173) |
| Week 16: Social Function Score | 2.455 (1.020 to 3.890) | 3.531 (2.105 to 4.957) | 4.817 (3.392 to 6.241) |
| Week 24: Social Function Score | 2.582 (1.240 to 3.924) | 5.426 (4.089 to 6.762) | 5.227 (3.889 to 6.564) |
| Week 8: Role-emotional Score | 1.980 (0.615 to 3.345) | 2.237 (0.877 to 3.598) | 1.987 (0.631 to 3.343) |
| Week 16: Role-emotional Score | 1.784 (0.316 to 3.253) | 2.496 (1.040 to 3.953) | 3.265 (1.810 to 4.720) |
| Week 24: Role-emotional Score | 2.201 (0.753 to 3.649) | 2.415 (0.976 to 3.853) | 3.531 (2.090 to 4.972) |
| Week 8: Mental Health Score | 2.124 (0.901 to 3.348) | 2.574 (1.358 to 3.790) | 3.126 (1.914 to 4.339) |
| Week 16: Mental Health Score | 2.360 (1.058 to 3.662) | 3.489 (2.200 to 4.777) | 3.984 (2.696 to 5.272) |
| Week 24: Mental Health Score | 2.062 (0.658 to 3.466) | 3.818 (2.425 to 5.211) | 4.356 (2.961 to 5.751) |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | 27.0 | 33.9 | 35.2 |
| Week 16 | 31.0 | 32.3 | 39.8 |
| Week 24 | 25.4 | 37.8 | 43.0 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | 31.0 | 33.9 | 46.1 |
| Week 16 | 29.4 | 48.0 | 50.0 |
| Week 24 | 28.6 | 51.2 | 53.9 |
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | 2.356 (1.081 to 3.632) | 3.643 (2.369 to 4.917) | 3.576 (2.306 to 4.845) |
| Week 16 | 2.164 (0.782 to 3.547) | 4.853 (3.478 to 6.228) | 4.544 (3.171 to 5.918) |
| Week 24 | 2.206 (0.773 to 3.638) | 5.609 (4.181 to 7.036) | 5.841 (4.416 to 7.267) |
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8 | 35.7 | 44.1 | 43.8 |
| Week 16 | 34.1 | 50.4 | 52.3 |
| Week 24 | 34.9 | 53.5 | 63.3 |
PROMIS-29 contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 numeric rating scale (NRS). The raw score of each domain is converted into a standardized score with a mean of 50 and a standard deviation (SD) of 10 for the general population in the US (T-Score).
| T-score | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8: Anxiety | -1.98 (-3.29 to -0.66) | -2.19 (-3.50 to -0.88) | -1.83 (-3.14 to -0.53) |
| Week 16: Anxiety | -2.30 (-3.63 to -0.97) | -3.08 (-4.40 to -1.75) | -2.23 (-3.54 to -0.91) |
| Week 24: Anxiety | -1.37 (-2.71 to -0.03) | -3.23 (-4.57 to -1.89) | -2.92 (-4.25 to -1.59) |
| Week 8: Depression | -0.86 (-2.07 to 0.35) | -2.42 (-3.63 to -1.21) | -1.54 (-2.74 to -0.34) |
| Week 16: Depression | -0.85 (-2.02 to 0.31) | -2.70 (-3.87 to -1.54) | -2.69 (-3.85 to -1.54) |
| Week 24: Depression | -0.85 (-2.12 to 0.42) | -3.40 (-4.66 to -2.14) | -2.67 (-3.92 to -1.41) |
| Week 8: Fatigue | -1.87 (-3.13 to -0.62) | -3.25 (-4.50 to -1.99) | -2.90 (-4.14 to -1.65) |
| Week 16: Fatigue | -2.29 (-3.57 to -1.02) | -4.26 (-5.53 to -2.99) | -4.14 (-5.40 to -2.88) |
| Week 24: Fatigue | -1.86 (-3.24 to -0.48) | -4.79 (-6.16 to -3.42) | -5.08 (-6.45 to -3.71) |
| Week 8: Pain Interference | -2.42 (-3.40 to -1.43) | -2.99 (-3.97 to -2.00) | -3.32 (-4.30 to -2.33) |
| Week 16: Pain Interference | -2.62 (-3.69 to -1.55) | -3.99 (-5.06 to -2.93) | -5.02 (-6.08 to -3.96) |
| Week 24: Pain Interference | -2.30 (-3.46 to -1.13) | -5.49 (-6.65 to -4.34) | -5.69 (-6.85 to -4.53) |
| Week 8: Physical Function | 1.34 (0.44 to 2.23) | 1.31 (0.42 to 2.20) | 2.37 (1.48 to 3.26) |
| Week 16: Physical Function | 1.53 (0.49 to 2.57) | 3.21 (2.17 to 4.24) | 4.12 (3.09 to 5.15) |
| Week 24: Physical Function | 1.34 (0.25 to 2.43) | 3.89 (2.81 to 4.98) | 5.05 (3.96 to 6.13) |
| Week 8: Sleep Disturbance | -1.22 (-2.23 to -0.21) | -1.91 (-2.92 to -0.91) | -2.09 (-3.09 to -1.09) |
| Week 16: Sleep Disturbance | -1.54 (-2.53 to -0.54) | -3.82 (-4.82 to -2.83) | -3.09 (-4.08 to -2.10) |
| Week 24: Sleep Disturbance | -1.17 (-2.25 to -0.09) | -3.48 (-4.56 to -2.40) | -2.46 (-3.53 to -1.38) |
| Week 8: Satisfaction-Social Role and Activity | 1.52 (0.39 to 2.64) | 3.13 (2.01 to 4.25) | 3.18 (2.06 to 4.29) |
| Week 16: Satisfaction-Social Role and Activity | 1.86 (0.65 to 3.08) | 3.93 (2.72 to 5.14) | 3.97 (2.76 to 5.17) |
| Week 24: Satisfaction-Social Role and Activity | 1.45 (0.22 to 2.69) | 4.90 (3.66 to 6.13) | 4.52 (3.29 to 5.75) |
| Week 8: Pain Intensity | -0.74 (-1.06 to -0.41) | -1.34 (-1.66 to -1.01) | -1.28 (-1.61 to -0.96) |
| Week 16: Pain Intensity | -0.73 (-1.09 to -0.37) | -1.63 (-1.98 to -1.27) | -2.03 (-2.38 to -1.67) |
| Week 24: Pain Intensity | -0.56 (-0.94 to -0.19) | -1.98 (-2.36 to -1.61) | -2.32 (-2.69 to -1.94) |
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Among ACR 20 responders | 8.571 ± 7.8995 | 9.242 ± 10.8473 | 6.684 ± 8.0948 |
| Among ACR 20 non-responders | 0.316 ± 6.8181 | 1.984 ± 7.8877 | 3.635 ± 6.8170 |
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Among ACR 20 responders | 67.9 | 68.2 | 73.7 |
| Among ACR 20 non-responders | 25.5 | 37.7 | 48.1 |
PROMIS-29 contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8: Anxiety | 41.3 | 41.7 | 39.1 |
| Week 16: Anxiety | -34.9 | 42.5 | 41.4 |
| Week 24: Anxiety | 34.9 | 45.7 | 42.2 |
| Week 8: Depression | 24.6 | 30.7 | 34.4 |
| Week 16: Depression | 25.4 | 35.4 | 33.6 |
| Week 24: Depression | 26.2 | 39.4 | 38.3 |
| Week 8: Fatigue | 34.1 | 39.4 | 42.2 |
| Week 16: Fatigue | 38.9 | 49.6 | 49.2 |
| Week 24: Fatigue | 32.5 | 48.8 | 55.5 |
| Week 8: Pain Interference | 34.9 | 41.7 | 43.8 |
| Week 16: Pain Interference | 39.7 | 47.2 | 56.3 |
| Week 24: Pain Interference | 33.3 | 54.3 | 57.0 |
| Week 8: Physical Function | 28.6 | 30.7 | 40.6 |
| Week 16: Physical Function | 28.6 | 44.1 | 45.3 |
| Week 24: Physical Function | 22.2 | 48.0 | 53.9 |
| Week 8: Sleep Disturbance | 35.7 | 38.6 | 39.1 |
| Week 16: Sleep Disturbance | 36.5 | 48.8 | 38.3 |
| Week 24: Sleep Disturbance | 31.0 | 48.8 | 40.6 |
| Week 8: Satisfaction-Social Role and Activity | 35.7 | 44.9 | 49.2 |
| Week 16: Satisfaction-Social Role and Activity | 37.3 | 46.5 | 46.1 |
| Week 24: Satisfaction-Social Role and Activity | 32.5 | 52.0 | 50.0 |
| Week 8: Pain Intensity | 15.1 | 22.8 | 26.6 |
| Week 16: Pain Intensity | 18.3 | 33.1 | 42.2 |
| Week 24: Pain Intensity | 15.1 | 37.0 | 45.3 |
PROMIS-29 contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 8: Anxiety | 33.3 | 37.0 | 29.7 |
| Week 16: Anxiety | 29.4 | 34.6 | 33.6 |
| Week 24: Anxiety | 28.6 | 41.7 | 38.3 |
| Week 8: Depression | 17.5 | 27.6 | 26.6 |
| Week 16: Depression | 19.0 | 32.3 | 28.9 |
| Week 24: Depression | 19.8 | 36.2 | 30.5 |
| Week 8: Fatigue | 27.8 | 29.1 | 33.6 |
| Week 16: Fatigue | 33.3 | 40.9 | 43.0 |
| Week 24: Fatigue | 31.0 | 45.7 | 47.7 |
| Week 8: Pain Interference | 22.2 | 29.9 | 35.9 |
| Week 16: Pain Interference | 29.4 | 38.6 | 43.8 |
| Week 24: Pain Interference | 23.8 | 46.5 | 51.6 |
| Week 8: Physical Function | 15.1 | 18.9 | 22.7 |
| Week 16: Physical Function | 18.3 | 26.8 | 32.8 |
| Week 24: Physical Function | 15.9 | 36.2 | 39.8 |
| Week 8: Sleep Disturbance | 24.6 | 24.4 | 27.3 |
| Week 16: Sleep Disturbance | 24.6 | 40.2 | 30.5 |
| Week 24: Sleep Disturbance | 21.4 | 37.0 | 32.8 |
| Week 8: Satisfaction-Social Role and Activity | 25.4 | 40.2 | 38.3 |
| Week 16: Satisfaction-Social Role and Activity | 30.2 | 42.5 | 39.8 |
| Week 24: Satisfaction-Social Role and Activity | 22.2 | 45.7 | 43.0 |
| Week 8: Pain Intensity | 5.6 | 6.3 | 6.3 |
| Week 16: Pain Intensity | 6.3 | 8.7 | 14.8 |
| Week 24: Pain Intensity | 4.0 | 18.1 | 18.0 |
ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 27.2 | 54.5 | 60.8 |
| Week 28 | 50.0 | 68.9 | 74.4 |
| Week 36 | 56.9 | 70.3 | 71.1 |
| Week 44 | 61.7 | 73.5 | 72.0 |
| Week 52 | 68.3 | 67.9 | 75.8 |
ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 9.6 | 30.9 | 36.8 |
| Week 28 | 21.4 | 42.6 | 39.2 |
| Week 36 | 32.7 | 47.1 | 44.6 |
| Week 44 | 30.8 | 51.3 | 46.0 |
| Week 52 | 36.5 | 43.4 | 55.6 |
ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 6.1 | 12.2 | 20.8 |
| Week 28 | 9.8 | 20.5 | 24.8 |
| Week 36 | 18.0 | 25.2 | 26.4 |
| Week 44 | 16.8 | 28.4 | 26.4 |
| Week 52 | 19.2 | 28.9 | 29.8 |
ACR components include swollen joint count (66 joints), tender joint count (68 joints), patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of the Health Assessment Questionnaire (HAQ-DI; a 20-question instrument assessing 8 functional areas; range: 0-3, 0=no difficulty, 3=inability to perform a task in that area), and CRP.
| percent change | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24: Swollen Joint Count | -48.33 ± 45.987 | -66.62 ± 47.086 | -73.23 ± 38.120 |
| Week 28: Swollen Joint Count | -59.95 ± 47.826 | -75.42 ± 33.774 | -80.93 ± 27.197 |
| Week 36: Swollen Joint Count | -70.50 ± 37.359 | -79.16 ± 35.141 | -80.19 ± 29.160 |
| Week 44: Swollen Joint Count | -72.63 ± 38.625 | -80.35 ± 34.653 | -82.46 ± 31.652 |
| Week 52: Swollen Joint Count | -78.23 ± 37.345 | -79.63 ± 36.471 | -86.73 ± 26.776 |
| Week 24: Tender Joint Count | -27.58 ± 53.737 | -53.73 ± 45.118 | -56.56 ± 41.774 |
| Week 28: Tender Joint Count | -42.99 ± 62.128 | -64.03 ± 40.678 | -66.68 ± 31.528 |
| Week 36: Tender Joint Count | -57.06 ± 43.351 | -68.44 ± 39.771 | -64.67 ± 41.606 |
| Week 44: Tender Joint Count | -60.08 ± 42.811 | -69.23 ± 51.229 | -71.90 ± 31.422 |
| Week 52: Tender Joint Count | -65.65 ± 37.682 | -72.39 ± 35.102 | -72.70 ± 37.487 |
| Week 24: Patient's Assessment of Pain | -6.05 ± 52.682 | -32.65 ± 45.343 | -38.90 ± 43.955 |
| Week 28: Patient's Assessment of Pain | -21.93 ± 52.597 | -38.86 ± 45.149 | -43.59 ± 39.524 |
| Week 36: Patient's Assessment of Pain | -27.61 ± 56.373 | -42.85 ± 43.952 | -47.23 ± 41.167 |
| Week 44: Patient's Assessment of Pain | -27.98 ± 64.080 | -45.27 ± 47.794 | -48.97 ± 36.509 |
| Week 52: Patient's Assessment of Pain | -35.64 ± 66.672 | -42.67 ± 47.250 | -50.03 ± 50.203 |
| Week 24: PtGA of Disease Activity | -7.63 ± 58.147 | -37.16 ± 39.760 | -40.27 ± 42.250 |
| Week 28: PtGA of Disease Activity | -21.74 ± 57.662 | -45.35 ± 41.564 | -37.62 ± 60.121 |
| Week 36: PtGA of Disease Activity | -26.51 ± 60.926 | -46.03 ± 39.547 | -45.17 ± 39.277 |
| Week 44: PtGA of Disease Activity | -21.76 ± 81.481 | -46.11 ± 40.973 | -45.84 ± 43.368 |
| Week 52: PtGA of Disease Activity | -35.17 ± 56.398 | -45.84 ± 42.176 | -47.85 ± 55.429 |
| Week 24: PGA of Disease Activity | -33.22 ± 34.014 | -53.43 ± 37.305 | -61.59 ± 31.445 |
| Week 28: PGA of Disease Activity | -53.88 ± 31.619 | -57.70 ± 33.724 | -65.96 ± 29.400 |
| Week 36: PGA of Disease Activity | -62.40 ± 29.215 | -64.51 ± 34.389 | -68.37 ± 27.206 |
| Week 44: PGA of Disease Activity | -64.93 ± 28.895 | -69.08 ± 30.743 | -72.65 ± 25.842 |
| Week 52: PGA of Disease Activity | -68.67 ± 32.861 | -68.83 ± 32.776 | -74.71 ± 25.456 |
| Week 24: HAQ-DI score | -7.65 ± 62.206 | -8.80 ± 148.199 | -31.18 ± 72.701 |
| Week 28: HAQ-DI score | -15.62 ± 51.720 | -29.10 ± 60.044 | -33.41 ± 72.942 |
| Week 36: HAQ-DI score | -15.37 ± 53.391 | -29.43 ± 73.712 | -32.74 ± 86.404 |
| Week 44: HAQ-DI score | -29.61 ± 45.603 | -34.54 ± 73.685 | -35.91 ± 80.885 |
| Week 52: HAQ-DI score | -28.42 ± 45.473 | -31.09 ± 60.232 | -46.13 ± 56.354 |
| Week 24: CRP | -13.58 ± 150.494 | -7.83 ± 101.789 | -6.48 ± 149.288 |
| Week 28: CRP | -8.67 ± 122.851 | -5.58 ± 99.590 | -10.30 ± 97.703 |
| Week 36: CRP | -17.33 ± 102.168 | -31.55 ± 50.560 | -14.65 ± 113.746 |
| Week 44: CRP | -29.10 ± 70.460 | -17.81 ± 76.247 | -4.39 ± 190.368 |
| Week 52: CRP | -1.68 ± 167.086 | -19.28 ± 69.875 | -15.76 ± 129.101 |
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -0.1217 ± 0.52442 | -0.3374 ± 0.56967 | -0.3740 ± 0.45914 |
| Week 28 | -0.2241 ± 0.50876 | -0.4004 ± 0.52303 | -0.3850 ± 0.46381 |
| Week 36 | -0.2602 ± 0.51278 | -0.4396 ± 0.54426 | -0.4132 ± 0.47155 |
| Week 44 | -0.3634 ± 0.53486 | -0.4672 ± 0.57140 | -0.4180 ± 0.51394 |
| Week 52 | -0.3642 ± 0.51084 | -0.4364 ± 0.56400 | -0.4970 ± 0.47990 |
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 36.0 | 53.2 | 57.8 |
| Week 28 | 40.2 | 61.5 | 61.5 |
| Week 36 | 41.7 | 60.4 | 61.9 |
| Week 44 | 50.0 | 58.7 | 62.4 |
| Week 52 | 54.3 | 57.4 | 68.5 |
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. Negative changes from baseline indicate improvement of arthritis.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -0.84 ± 1.043 | -1.49 ± 1.140 | -1.57 ± 1.045 |
| Week 28 | -1.33 ± 1.121 | -1.71 ± 1.126 | -1.67 ± 1.020 |
| Week 36 | -1.60 ± 1.123 | -1.96 ± 1.145 | -1.78 ± 1.054 |
| Week 44 | -1.69 ± 1.224 | -1.96 ± 1.226 | -1.92 ± 1.116 |
| Week 52 | -1.84 ± 1.087 | -2.03 ± 1.250 | -1.99 ± 1.062 |
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. DAS28 (CRP) response criteria was defined as follows: Good response: \<=3.2 at visit and \>1.2 improvement; Moderate response: \>3.2 at visit and \>1.2 improvement or \<=5.1 at visit and \>0.6-1.2 improvement; No response: \<=0.6 improvement, or \>5.1 at visit and \<=1.2 improvement. The values are 0=best to 10=worst. A DAS28 (CRP) responder was defined as achieving a good or moderate DAS28 response at a specific visit.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 51.8 | 74.6 | 78.4 |
| Week 28 | 73.6 | 83.3 | 83.9 |
| Week 36 | 76.4 | 89.0 | 86.8 |
| Week 44 | 80.0 | 86.8 | 89.5 |
| Week 52 | 86.4 | 88.4 | 87.8 |
DAS28 based on CRP is an index combining tender joints (28 joints), swollen joints (28 joints), CRP and patient's global assessment of disease activity. The set of 28 joint count is based on evaluation of the shoulder, elbow, wrist, metacarpophalangeal (MCP) MCP1 to MCP5, proximal interphalangeal (PIP) PIP1 to PIP5 joints of both the upper right extremity and the upper left extremity as well as the knee joints of lower right and lower left extremities. The values are 0=best to 10=worst. DAS28 (CRP) remission was defined as DAS28 (CRP) value \<2.6 at the analysis visit.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 14.9 | 24.6 | 36.8 |
| Week 28 | 26.4 | 37.5 | 38.7 |
| Week 36 | 39.1 | 40.7 | 40.5 |
| Week 44 | 38.1 | 45.6 | 51.6 |
| Week 52 | 37.9 | 43.8 | 56.1 |
HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning and a decrease of 0.35 from baseline in HAQ-DI score indicates a meaningful improvement.
| percentage of participants | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|
| Percentage of Participants Who Maintained a HAQ-DI Response (>=0.35 Improvement From Baseline in HAQ-DI Score) at Week 52 Among Participants Who Achieved a HAQ-DI Response at Week 24 | 84.9 | 87.3 |
The modified PsARC response was defined as improvement in at least 2 of the four criteria: \>=30% decrease in swollen joint count, \>=30% decrease in tender joint count, \>=20% improvement in patient's Global Assessment of Disease Activity (arthritis) on a VAS (0-100 mm, 0=excellent and 100= poor), \>=20% improvement in physician's Global Assessment of Disease Activity using VAS (VAS: 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), and at least one of the 2 joint criteria with no deterioration in the other criteria.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 37.2 | 63.1 | 74.4 |
| Week 28 | 64.9 | 78.7 | 82.3 |
| Week 36 | 68.8 | 80.5 | 80.0 |
| Week 44 | 73.8 | 81.9 | 80.0 |
| Week 52 | 73.8 | 83.8 | 83.9 |
DAPSA assessed the joint domain of PsA and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (mg/dL), patient assessment of pain (0-10cm VAS, 0=no pain, 10=worst possible pain), and patient's global assessment of disease activity on arthritis (0 to 10cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -12.962 ± 17.9137 | -23.373 ± 20.2784 | -20.530 ± 13.2678 |
| Week 28 | -18.632 ± 19.4997 | -26.790 ± 19.3655 | -22.766 ± 12.8366 |
| Week 36 | -22.360 ± 18.8976 | -30.070 ± 21.0899 | -24.067 ± 14.0976 |
| Week 44 | -23.602 ± 19.9198 | -30.312 ± 22.5854 | -26.010 ± 15.3230 |
| Week 52 | -26.058 ± 18.6507 | -30.906 ± 23.0188 | -26.562 ± 15.1985 |
In PASI, each area (head, trunk, upper and lower extremities) was assessed separately for % of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score range from 0 to 72. Higher scores=more severe disease. PASI75 response: \>=75% improvement in PASI score from baseline. Modified PsARC response: improvement in at least 2 of 4 criteria: \>=30% decrease in SJC and TJC, \>=20% improvement in PtGA of Disease Activity (arthritis) on VAS (0-100 mm, 0=excellent and 100=poor), \>=20% improvement in PGA of Disease Activity on VAS (VAS: 0-100 mm, 0=no arthritis and 100=extremely active arthritis), and at least 1 of 2 joint criteria with no deterioration in other criteria.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 8.8 | 50.6 | 63.6 |
| Week 52 | 69.2 | 70.7 | 79.5 |
In PASI, each area (head, trunk, upper and lower extremities) was assessed for % of area involved and translated to numeric score from 0 (no involvement) to 6 (90-100% involvement) and for erythema, induration, and scaling, each rated on scale of 0 to 4. PASI produces numeric score from 0 to 72. Higher scores=more severe disease. PASI 75: \>=75% improvement in PASI score from baseline. ACR 20: \>=20% improvement in SJC (66 joints)+TJC (68 joints) and \>=20% improvement in 3 of 5: patient's assessment of pain (VAS; 0-100 mm, 0=no pain to 100=worst possible pain), PtGA of disease activity (VAS; 0-100 mm, 0=excellent to 100=poor), PGA of disease activity (VAS; 0-100 mm, 0=no arthritis to 100=extremely active arthritis), patient's assessment of physical function (HAQ-DI -20-question instrument; range- 0=no difficulty to 3=inability to perform task) and CRP.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 10.3 | 40.7 | 53.4 |
| Week 52 | 64.6 | 58.7 | 73.9 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. Negative changes from baseline indicate improvement of psoriasis.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -3.046 ± 9.3053 | -9.968 ± 10.0178 | -11.614 ± 10.3771 |
| Week 52 | -10.565 ± 8.8792 | -10.431 ± 11.0277 | -11.988 ± 10.3067 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 75 response: \>=75% improvement in PASI score from baseline.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 20.6 | 76.5 | 87.5 |
| Week 52 | 84.8 | 80.0 | 94.3 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 90 response: \>=90% improvement in PASI score from baseline.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 13.2 | 50.6 | 63.6 |
| Week 52 | 72.7 | 66.7 | 76.1 |
PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severity. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. PASI 100 response: 100% improvement in PASI score from baseline.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 7.4 | 25.9 | 45.5 |
| Week 52 | 62.1 | 48.0 | 64.8 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 35.1 | 53.7 | 55.6 |
| Week 36 | 44.9 | 53.8 | 55.0 |
| Week 52 | 52.9 | 53.5 | 62.9 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better outcome, with an increase of 5 points considered to be clinically meaningful.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 29.8 | 39.0 | 44.4 |
| Week 36 | 39.3 | 39.5 | 49.2 |
| Week 52 | 37.5 | 46.5 | 47.6 |
MDA is a measure that defines a satisfactory state of disease activity that includes the 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity, physical function, and enthesitis). A participant was considered as having achieved the PsA MDA at a visit if the participant has fulfilled at least 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 12.3 | 23.6 | 31.2 |
| Week 52 | 31.1 | 33.9 | 40.3 |
GRACE index is a composite PsA disease activity score converted from AMDF, which was derived from TJC (0-68) and SJC (0-66), HAQ-DI (0-3), patient's global assessment of disease activity on arthritis and psoriasis (0-100 mm, 0=excellent and 100= poor), patient's assessment of skin disease activity (0-100 mm, 0=excellent and 100=poor), patient's global assessment of disease activity on arthritis (0-100 mm, 0=excellent and 100=poor), PASI (0-72), and PsA Quality of Life Index (derived as PsAQOL =25.355 + \[2.367\*HAQ-DI\] - \[0.234\*SF-PCS\] - \[0.244\*SF-MCS\]), where HAQ-DI: HAQ-DI score (0-3, 0=least difficulty and 3=extreme difficulty), SF-PCS (Score ranges from 0 to 100, higher scores= better quality of life) and SF-MCS (score ranges from 0 to 100, higher scores= better quality of life). The total score is from 0-10, where lower score indicates better response. Higher score indicates more active disease activity. Negative change from baseline indicates improvement of PsA disease activity.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -0.998 ± 1.4808 | -2.493 ± 1.5195 | -2.751 ± 1.5060 |
| Week 52 | -2.829 ± 1.5773 | -3.112 ± 1.7479 | -3.364 ± 1.4638 |
PASDAS (score range of 0 to 10, where higher score indicated more severe disease) is a compositive score of overall disease activity combining Patient's Global Assessment of Disease Activity (arthritis and psoriasis, using VAS \[0-100 mm, 0=excellent and 100= poor), Physician's Global Assessment of Disease Activity (using VAS \[0-100 mm, 0=no arthritis activity and 100=extremely active arthritis\]), swollen joint count (0-66 joints), tender joint count (0-68 joints), CRP (mg/L), enthesitis based on LEI (0-6), tender dactylitis count (scoring each digit from 0-3 and recoding to 0-1, where any score \> 0 equaled 1), and the PCS score of the SF-36 health survey. The cutoffs for disease activity were 3.2 (low) to 5.4 (high). Negative changes from baseline indicate improvement of overall disease activity.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -1.140 ± 1.4036 | -2.246 ± 1.4978 | -2.413 ± 1.3906 |
| Week 52 | -2.748 ± 1.4706 | -2.897 ± 1.6788 | -3.026 ± 1.4446 |
ACR 20 response was defined as \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|
| Percentage of Participants Who Maintained an ACR 20 Response at Week 52 Among Participants Who Achieved an ACR 20 Response at Week 24 | 88.5 | 90.8 |
ACR 50 response was defined as \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|
| Percentage of Participants Who Maintained an ACR 50 Response at Week 52 Among Participants Who Achieved an ACR 50 Response at Week 24 | 83.8 | 91.3 |
ACR 70 response was defined as \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of the 5 assessments: patient's assessment of pain using VAS (0-100 millimeters \[mm\], 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by HAQ-DI (defined as a 20-question instrument assessing 8 functional areas; range: 0-3, 0=indicating no difficulty, 3=indicating inability to perform a task in that area), and CRP.
| percentage of participants | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|
| Percentage of Participants Who Maintained an ACR 70 Response at Week 52 Among Participants Who Achieved an ACR 70 Response at Week 24 | 80.0 | 84.6 |
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a self-assessment tool that consists of 6 questions relating to the 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. The first 5 items were scored on a 10 centimeter (cm) VAS ranging from 0=none to 10=very severe. Quantitative morning stiffness was scored on a 10cm VAS ranging from 0=0 hours to 10=2 or more hours. The 2 scores for qualitative and quantitative morning stiffness were averaged, and the total BASDAI score was the average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity and an improvement of 50% from baseline is considered clinically meaningful. Only participants with spondylitis with peripheral arthritis as their primary arthritic presentation of PsA completed the BASDAI indicate the degree of their symptoms over the past week.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24: Participants with >=20% Improvement | 38.1 | 70.8 | 65.0 |
| Week 52: Participants with >=20% Improvement | 66.7 | 72.7 | 85.0 |
| Week 24: Participants with >=50% Improvement | 19.0 | 41.7 | 35.0 |
| Week 52: Participants with >=50% Improvement | 52.4 | 59.1 | 50.0 |
| Week 24: Participants with >=70% Improvement | 14.3 | 29.2 | 5.0 |
| Week 52: Participants with >=70% Improvement | 28.6 | 40.9 | 20.0 |
| Week 24: Participants with >=90% Improvement | 0 | 16.7 | 0 |
| Week 52: Participants with >=90% Improvement | 9.5 | 13.6 | 15.0 |
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). A LEI score of 0 at a post baseline visit indicates resolution of enthesitis when baseline LEI\>0.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 31.0 | 40.8 | 49.3 |
| Week 36 | 49.3 | 52.9 | 58.0 |
| Week 44 | 58.2 | 46.4 | 71.8 |
| Week 52 | 69.8 | 56.3 | 62.9 |
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. Higher score indicates more severe dactylitis. Resolution of dactylitis was defined as a dactylitis score of 0 with the baseline dactylitis score \>0.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 61.7 | 67.3 | 64.9 |
| Week 36 | 79.5 | 67.4 | 82.9 |
| Week 44 | 84.8 | 76.1 | 83.8 |
| Week 52 | 81.4 | 79.5 | 78.4 |
Enthesitis was assessed using the Spondyloarthritis Research Consortium of Canada (SPARCC). The SPARCC developed a measure for enthesitis in general spondyloarthritis which evaluates the presence or absence of pain by applying local pressure to the following entheses: supraspinatus insertion (left and right), medial epicondyle humerus (left and right), lateral epicondyle humerus (left and right), greater trochanter (left and right), quadriceps-to-patella (left and right), patellar-tibia (left and right), achilles tendon insertion (left and right), plantar fascia (left and right). Tenderness on examination was recorded as either present (1) or absent (0) for each of the 16 sites for an overall score range of 0-16. Higher scores indicate more severe enthesitis. Negative changes from baseline indicate improvement of enthesitis.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -1.9 ± 3.55 | -2.7 ± 3.68 | -3.0 ± 3.60 |
| Week 36 | -3.1 ± 3.61 | -3.4 ± 3.90 | -3.6 ± 3.52 |
| Week 44 | -3.6 ± 3.67 | -3.6 ± 3.82 | -4.1 ± 3.55 |
| Week 52 | -3.9 ± 3.57 | -4.1 ± 4.04 | -4.0 ± 3.51 |
Enthesitis was assessed using the LEI, a tool developed to assess enthesitis in participants with PsA and evaluates the presence (score of 1) or absence (score of 0) of pain by applying local pressure to the following entheses: left and right lateral epicondyle humerus, left and right medial femoral condyle, and left and right achilles tendon insertion. The enthesitis index score is a total score of the 6 evaluated sites from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness). Negative changes from baseline indicate improvement of enthesitis.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -1.0 ± 1.68 | -1.2 ± 1.95 | -1.8 ± 1.93 |
| Week 36 | -1.4 ± 1.73 | -1.3 ± 2.04 | -2.0 ± 1.68 |
| Week 44 | -1.6 ± 1.90 | -1.6 ± 1.70 | -2.4 ± 1.68 |
| Week 52 | -1.9 ± 1.65 | -1.8 ± 1.66 | -2.0 ± 1.87 |
The presence and severity of dactylitis was assessed in both hands and feet using a scoring system from 0 to 3 (0-no dactylitis, 1-mild dactylitis, 2-moderate dactylitis, and 3-severe dactylitis) for each digit. The results were summed to produce a final score ranging from 0 to 60. A higher score indicates more severe dactylitis. Negative changes from baseline indicate improvement in dactylitis.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | -4.0 ± 6.08 | -6.2 ± 10.31 | -6.6 ± 11.08 |
| Week 36 | -6.0 ± 7.17 | -6.4 ± 10.91 | -7.7 ± 11.58 |
| Week 44 | -5.3 ± 5.61 | -7.2 ± 10.57 | -7.5 ± 11.41 |
| Week 52 | -5.7 ± 5.86 | -7.8 ± 10.55 | -7.6 ± 10.91 |
A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and \>= 2 grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 8.8 | 38.3 | 54.5 |
| Week 52 | 66.2 | 53.3 | 67.0 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 2.700 ± 7.1649 | 6.505 ± 7.7137 | 6.560 ± 7.7566 |
| Week 36 | 5.456 ± 8.0353 | 7.439 ± 8.5626 | 7.162 ± 7.9890 |
| Week 52 | 6.905 ± 7.9376 | 7.278 ± 8.0648 | 8.517 ± 8.2717 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The MCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 1.827 ± 8.1508 | 3.027 ± 10.6157 | 3.796 ± 8.7396 |
| Week 36 | 3.612 ± 7.2322 | 4.300 ± 10.2373 | 4.326 ± 9.2709 |
| Week 52 | 4.240 ± 8.1200 | 5.139 ± 9.1719 | 4.931 ± 8.9482 |
SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales: physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health. The scores 0-100 (where higher scores indicated a better quality of life) from each subscale of SF-36 were normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. Higher score indicates better health status. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24: Physical Functioning | 1.914 ± 8.8644 | 6.006 ± 7.9608 | 6.652 ± 8.4730 |
| Week 36: Physical Functioning | 5.008 ± 8.6461 | 6.900 ± 8.5458 | 7.114 ± 8.8941 |
| Week 52: Physical Functioning | 6.257 ± 8.3753 | 7.000 ± 8.0953 | 8.720 ± 8.9738 |
| Week 24: Role-physical | 3.053 ± 7.6460 | 5.239 ± 8.2864 | 5.215 ± 7.5241 |
| Week 36: Role-physical | 4.701 ± 8.1572 | 6.245 ± 7.8346 | 6.250 ± 7.9040 |
| Week 52: Role-physical | 5.873 ± 8.8847 | 6.126 ± 8.1008 | 7.063 ± 8.2579 |
| Week 24: Bodily Pain | 3.388 ± 7.2056 | 7.058 ± 8.8315 | 7.215 ± 9.1129 |
| Week 36: Bodily Pain | 6.477 ± 8.6363 | 8.487 ± 8.8135 | 7.348 ± 9.0965 |
| Week 52: Bodily Pain | 8.331 ± 8.1585 | 8.781 ± 8.5691 | 8.958 ± 9.1783 |
| Week 24: General Health | 1.819 ± 6.9497 | 4.361 ± 7.5573 | 5.066 ± 7.1334 |
| Week 36: General Health | 3.742 ± 8.2079 | 5.638 ± 8.4919 | 5.540 ± 7.4840 |
| Week 52: General Health | 4.677 ± 7.8944 | 5.547 ± 7.8712 | 6.442 ± 7.9374 |
| Week 24: Vitality | 2.684 ± 9.0049 | 5.652 ± 9.6943 | 6.158 ± 7.8842 |
| Week 36: Vitality | 6.303 ± 9.0307 | 7.065 ± 8.6659 | 7.353 ± 8.7656 |
| Week 52: Vitality | 7.742 ± 8.7476 | 7.558 ± 9.1600 | 8.218 ± 8.5308 |
| Week 24: Social Function | 2.419 ± 8.8289 | 5.666 ± 9.3449 | 4.932 ± 9.5887 |
| Week 36: Social Function | 4.873 ± 9.1477 | 5.899 ± 9.9762 | 5.598 ± 10.5240 |
| Week 52: Social Function | 5.351 ± 8.9264 | 6.729 ± 8.4844 | 6.428 ± 10.1397 |
| Week 24: Role-emotional | 1.833 ± 9.0800 | 2.265 ± 10.6155 | 3.706 ± 9.3529 |
| Week 36: Role-emotional | 3.580 ± 8.5353 | 4.301 ± 10.1127 | 3.685 ± 10.5307 |
| Week 52: Role-emotional | 4.520 ± 8.8658 | 4.979 ± 10.2956 | 4.830 ± 9.9053 |
| Week 24: Mental Health | 1.905 ± 8.1196 | 4.062 ± 10.0610 | 4.873 ± 8.6431 |
| Week 36: Mental Health | 3.472 ± 7.0761 | 5.056 ± 9.7930 | 5.559 ± 8.9957 |
| Week 52: Mental Health | 4.251 ± 8.3059 | 5.553 ± 8.4255 | 6.223 ± 8.8360 |
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
| units on a scale | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 2.605 ± 8.3142 | 5.862 ± 10.3941 | 5.576 ± 7.7670 |
| Week 36 | 5.981 ± 8.3846 | 7.252 ± 9.7182 | 5.917 ± 8.5123 |
| Week 52 | 6.577 ± 9.4105 | 7.482 ± 9.6342 | 6.911 ± 8.3986 |
The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.
| percentage of participants | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24 | 41.2 | 55.3 | 64.8 |
| Week 36 | 60.7 | 58.0 | 66.1 |
| Week 52 | 63.5 | 61.4 | 63.7 |
PROMIS-29 contains 4 items for each of seven PROMIS domains (Anxiety, Depression, Fatigue, Pain Interference, Physical Function, Sleep Disturbance, and Satisfaction-Social Role and Activity. PROMIS-29 also includes an additional pain intensity 0-10 NRS. The raw score of each domain is converted into a standardized score with a mean of 50 and a SD of 10 for the general population in the US (T-Score).
| T-score | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w |
|---|---|---|---|
| Week 24: Anxiety Score | -1.482 ± 8.3526 | -3.680 ± 9.8122 | -3.115 ± 7.9491 |
| Week 36: Anxiety Score | -2.410 ± 7.6503 | -3.929 ± 8.9614 | -2.961 ± 8.4679 |
| Week 52: Anxiety Score | -3.640 ± 8.3601 | -4.279 ± 9.6488 | -3.075 ± 8.5784 |
| Week 24: Depression Score | -0.601 ± 8.3133 | -3.963 ± 8.5473 | -2.706 ± 8.1872 |
| Week 36: Depression Score | -0.933 ± 7.1629 | -3.916 ± 8.6211 | -2.987 ± 7.8786 |
| Week 52: Depression Score | -2.488 ± 7.8259 | -4.004 ± 7.5271 | -2.985 ± 8.0519 |
| Week 24: Fatigue Score | -2.104 ± 7.5625 | -4.780 ± 9.7044 | -4.757 ± 7.7779 |
| Week 36: Fatigue Score | -5.533 ± 8.3256 | -5.857 ± 8.8525 | -5.693 ± 9.3854 |
| Week 52: Fatigue Score | -5.720 ± 9.0165 | -6.773 ± 8.5608 | -5.583 ± 8.1099 |
| Week 24: Pain Interference Score | -2.811 ± 5.9890 | -5.810 ± 7.5201 | -5.423 ± 7.1593 |
| Week 36: Pain Interference Score | -5.344 ± 7.2500 | -6.754 ± 8.0520 | -5.882 ± 7.5121 |
| Week 52: Pain Interference Score | -6.334 ± 6.9940 | -6.972 ± 8.2440 | -6.242 ± 7.4767 |
| Week 24: Physical Function Score | 1.682 ± 5.9909 | 4.101 ± 7.1353 | 5.030 ± 6.5259 |
| Week 36: Physical Function Score | 3.093 ± 6.5712 | 4.970 ± 7.0012 | 5.264 ± 7.0643 |
| Week 52: Physical Function Score | 4.245 ± 6.1363 | 5.033 ± 7.0184 | 5.920 ± 6.9852 |
| Week 24: Sleep Disturbance Score | -1.497 ± 5.7591 | -3.750 ± 6.8758 | -2.549 ± 6.7263 |
| Week 36: Sleep Disturbance Score | -2.767 ± 5.7630 | -3.853 ± 6.5505 | -4.096 ± 6.8724 |
| Week 52: Sleep Disturbance Score | -3.290 ± 5.8368 | -4.375 ± 6.5738 | -3.856 ± 6.1181 |
| Week24:Satisfaction-Social Role and Activity Score | 1.666 ± 7.2572 | 5.308 ± 8.5808 | 4.235 ± 7.4745 |
| Week36:Satisfaction-Social Role and Activity Score | 4.120 ± 8.1899 | 6.270 ± 8.8798 | 4.517 ± 7.9605 |
| Week52:Satisfaction-Social Role and Activity Score | 4.885 ± 8.7421 | 6.607 ± 7.8438 | 5.347 ± 8.1806 |
| Week 24: Pain Intensity Score | -0.737 ± 2.0911 | -2.098 ± 2.4104 | -2.320 ± 2.4449 |
| Week 36: Pain Intensity Score | -1.720 ± 2.3424 | -2.496 ± 2.4212 | -2.488 ± 2.4018 |
| Week 52: Pain Intensity Score | -2.462 ± 2.3480 | -2.711 ± 2.4844 | -2.847 ± 2.5377 |
Collected over Up to Week 60. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (CP) | 2/126 (1.6%) | 5/126 (4%) | 25/126 (19.8%) |
| Guselkumab 100 mg q8w (CP) | 0/127 (0%) | 4/127 (3.1%) | 38/127 (29.9%) |
| Guselkumab 100 mg q4w (CP) | 0/128 (0%) | 0/128 (0%) | 28/128 (21.9%) |
| Placebo to Guselkumab 100 mg q4w (ACP Through Week 60) | 0/114 (0%) | 4/114 (3.5%) | 25/114 (21.9%) |
| Guselkumab 100 mg q8w (Through Week 60) | 0/127 (0%) | 8/127 (6.3%) | 48/127 (37.8%) |
| Guselkumab 100 mg q4w (Through Week 60) | 0/128 (0%) | 4/128 (3.1%) | 41/128 (32%) |
| Event | Placebo (CP) | Guselkumab 100 mg q8w (CP) | Guselkumab 100 mg q4w (CP) | Placebo to Guselkumab 100 mg q4w (ACP Through Week 60) | Guselkumab 100 mg q8w (Through Week 60) | Guselkumab 100 mg q4w (Through Week 60) |
|---|---|---|---|---|---|---|
| Atrial FibrillationCardiac disorders | 0/126 | 0/127 | 0/128 | 1/114 | 0/127 | 0/128 |
| PyelonephritisInfections and infestations | 0/126 | 0/127 | 0/128 | 1/114 | 0/127 | 0/128 |
| UrosepsisInfections and infestations | 0/126 | 0/127 | 0/128 | 1/114 | 0/127 | 0/128 |
| Head InjuryInjury, poisoning and procedural complications | 0/126 | 0/127 | 0/128 | 1/114 | 0/127 | 0/128 |
| Cardiac FailureCardiac disorders | 1/126 | 0/127 | 0/128 | 0/114 | 0/127 | 0/128 |
| PainGeneral disorders | 1/126 | 0/127 | 0/128 | 0/114 | 0/127 | 0/128 |
| Abscess LimbInfections and infestations | 1/126 | 0/127 | 0/128 | 0/114 | 0/127 | 0/128 |
| PneumoniaInfections and infestations | 1/126 | 0/127 | 0/128 | 0/114 | 0/127 | 0/128 |
| Upper Respiratory Tract InfectionInfections and infestations | 1/126 | 0/127 | 0/128 | 0/114 | 0/127 | 0/128 |
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 1/126 | 0/127 | 0/128 | 0/114 | 0/127 | 0/128 |
| Event | Placebo (CP) | Guselkumab 100 mg q8w (CP) | Guselkumab 100 mg q4w (CP) | Placebo to Guselkumab 100 mg q4w (ACP Through Week 60) | Guselkumab 100 mg q8w (Through Week 60) | Guselkumab 100 mg q4w (Through Week 60) |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 8/126 | 16/127 | 7/128 | 13/114 | 21/127 | 14/128 |
| Upper Respiratory Tract InfectionInfections and infestations | 8/126 | 7/127 | 11/128 | 8/114 | 10/127 | 16/128 |
| Aspartate Aminotransferase IncreasedInvestigations | 3/126 | 9/127 | 3/128 | 4/114 | 11/127 | 6/128 |
| BronchitisInfections and infestations | 1/126 | 5/127 | 1/128 | 3/114 | 9/127 | 2/128 |
| Alanine Aminotransferase IncreasedInvestigations | 3/126 | 8/127 | 5/128 | 4/114 | 9/127 | 9/128 |
| EnthesopathyMusculoskeletal and connective tissue disorders | 6/126 | 6/127 | 6/128 | 0/114 | 7/127 | 8/128 |
Full Analysis Set (FAS) 1 included all participants who received at least 1 dose (complete/partial) of study agent according to randomized treatment group regardless of treatment actually received.
| Age, Continuous(years) | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w | Total |
|---|---|---|---|---|
| Mean | 49 ± 11.1 | 48.9 ± 11.52 | 47.4 ± 11.59 | 48.4 ± 11.39 |
| Sex: Female, Male(Participants) | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w | Total |
|---|---|---|---|---|
| Female | 65 | 59 | 62 | 186 |
| Male | 61 | 68 | 66 | 195 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 0 | 4 |
| Not Hispanic or Latino | 122 | 124 | 128 | 374 |
| Unknown or Not Reported | 2 | 1 | 0 | 3 |
| Race (NIH/OMB)(Participants) | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 12 | 10 | 7 | 29 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 112 | 116 | 121 | 349 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 0 | 2 |
| Region of Enrollment(Participants) | Placebo | Guselkumab 100 mg q8w | Guselkumab 100 mg q4w | Total |
|---|---|---|---|---|
| AUSTRALIA | 5 | 8 | 4 | 17 |
| CANADA | 8 | 3 | 4 | 15 |
| CZECH REPUBLIC | 5 | 4 | 3 | 12 |
| GERMANY | 3 | 10 | 10 | 23 |
| HUNGARY | 3 | 4 | 9 | 16 |
| MALAYSIA | 5 | 1 | 2 | 8 |
| POLAND | 37 | 36 | 34 | 107 |
| RUSSIAN FEDERATION | 22 | 19 | 23 | 64 |
| SOUTH KOREA | 3 | 1 | 0 | 4 |
| SPAIN | 5 | 6 | 1 | 12 |
| TAIWAN | 4 | 7 | 5 | 16 |
| UKRAINE | 19 | 22 | 29 | 70 |
| UNITED STATES | 7 | 6 | 4 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2017 to primary completion in Mar 2019, 18 months.
Results were first posted in Oct 2020, 1 year 7 months after primary completion. A results delay was requested in Mar 2020.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 18 months is below that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen Research & Development, LLC →